Increasing HIV/STI Home Testing Via a Digital Intervention Among Black Women
Launched by JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH · May 19, 2022
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on helping Black women who are at risk for HIV and sexually transmitted infections (STIs) to get tested for these conditions more easily from home. The study is testing a digital program that provides support and information on how to use home testing kits, connect with healthcare services, and learn about preventive treatments like PrEP, which can help reduce the risk of getting HIV.
To participate, women must be between the ages of 15 and 59, identify as Black or African-American, and live in urban areas like Austin, Dallas, Houston, or San Antonio in Texas. They should not have tested for HIV or STIs in the past year and should have had condom-less sex in the past six months. Participants will receive guidance through the digital program, making it easier for them to get tested and access care. This trial aims to make testing more accessible and tailored to the needs of the community, ultimately helping to improve health outcomes for women at risk.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 15 - 59 years of age
- • Identify as a cisgender woman
- • Identify as Black/African-American (Black/African American mixed race/ethnicity is included)
- • Read/speak/type in English
- • Have not tested for HIV/STIs in the past 12 months
- • Live in urban or suburban areas in Austin, Dallas, Houston, or San Antonio, Texas
- • Had condom-less sex in the past 6 months
- • Have access to a device (i.e., smart phone, tablet, or computer/laptop)
- • Have access to the internet
- * Reports at least one of the following:
- • A sexual partner who is living with HIV
- • Does not use or uses condoms inconsistently for vaginal/anal sex
- • Injects drugs with a partner who is living with HIV
- • Shared drug preparation or injection equipment with others
- Exclusion Criteria:
- • Over the age of 59 or younger than 15 years
- • Identify as any gender other than a cisgender woman
- • Identify as any race/ethnicity other than Black/African-American
- • Are unable to fluently speak, read, or type in English
- • Had an HIV/STI test within the past 12 months
- • Live in rural areas of Texas or urban/suburban areas other than Austin, Dallas, Houston, or San Antonio, Texas
- • Use condoms 100% of the time during vaginal/anal sex in the past 6 months
- • Do not have access to a device (i.e., smart phone, tablet, or computer/laptop)
- • Do not have access to the internet
- • Reports that they do not have a sexual partner who is living with HIV, always uses condoms for vaginal/anal sex, does not inject drugs with a partner living with HIV, and does not share drug preparation or injection equipment with others.
About Johns Hopkins Bloomberg School Of Public Health
The Johns Hopkins Bloomberg School of Public Health is a leading institution dedicated to advancing public health research and education. Renowned for its rigorous academic programs and commitment to improving global health outcomes, the School conducts innovative clinical trials that address pressing health challenges. With a focus on evidence-based practices, multidisciplinary collaboration, and community engagement, the Bloomberg School leverages its extensive resources and expertise to contribute to the development of effective public health interventions and policies. Through its research endeavors, the School aims to enhance population health and inform health policy both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Austin, Texas, United States
Austin, Texas, United States
Dallas, Texas, United States
Houston, Texas, United States
San Antonio, Texas, United States
Patients applied
Trial Officials
Liesl A Nydegger, PhD
Principal Investigator
Johns Hopkins Bloomberg School of Public Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials